Duration of hospital stay (days) for 'rescue' therapy · participants with chronic neuromuscular diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PCF · participants with chronic neuromuscular diseases
1 finding from 1 review
Any adverse events · participants with chronic neuromuscular diseases
1 finding from 1 review
no estimate extracted
64 participants
Very low
Quality of life for 'maintenance' therapy · participants with chronic neuromuscular diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant preference or satisfaction for 'rescue' and 'maintenance' therapy · participants with chronic neuromuscular diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost of the intervention · Dental healthcare providers (dentist, dental surgery assistant, dental hygienist, dental technologist, dental laboratory staff, dental…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Acceptability and feasibility of the intervention to patients and dentists · Dental healthcare providers (dentist, dental surgery assistant, dental hygienist, dental technologist, dental laboratory staff, dental…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Little or no pain at < 24 hours · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Little or no pain at 1 to 3 days · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes little or no pain at 1 to 3 days compared with combination (paracetamol and opioid) analgesic (very low certainty).
2 findings from 1 review
Swelling (7th day) · people with acute soft tissue injury, such as ankle sprain
1 finding from 1 review
Return to function on day 7 or later Assessed as 'cure' · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes return to function on day 7 or later Assessed as 'cure' compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes gastrointestinal adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review
Neurological adverse effects · people with acute soft tissue injury, such as ankle sprain
It is very uncertain whether NSAID changes neurological adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).
1 finding from 1 review
Early re‐injury (with 3 months) · people with acute soft tissue injury, such as ankle sprain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
1 finding from 1 review
Intervention not reported
Total studies: 282 RCTs Total participants: 50,812 Number of treatments: 65 Geometry of the network** · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…
1 finding from 1 review
Intervention not reported
Droperidol (41 RCTs; 6156 participants) · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…
1 finding from 1 review